Patent analysis for coagulation factor Xa inhibitors
10.11665/j.issn.1000-5048.20190314
- VernacularTitle:凝血因子Ⅹa抑制剂专利技术分析
- Author:
Dongmei ZHAO
1
;
Changjin FANG
;
Zhixia QIU
Author Information
1. 国家知识产权局专利局专利审查协作江苏中心
- Publication Type:Journal Article
- Keywords:
coagulation factor Xa inhibitor;
xaban;
antithrombus;
patent analysis patent arrangement
- From:
Journal of China Pharmaceutical University
2019;50(3):364-373
- CountryChina
- Language:Chinese
-
Abstract:
Anticoagulant drugs are widely used in the prevention and treatment of thromboembolic diseases. In recent years, coagulation factor Xa inhibitors have become a hot spot for the development of new anticoagulant drugs. However, the anticoagulant drugs currently used still have side-effects such as increased bleeding risk. This paper analyzes the patent applications of coagulation factor Xa inhibitors, and summarizes the development route of patent application of Bristol-Myers Squibb Company and Guangdong Dongyang Pharmaceutical Co. , Ltd. as representatives of key enterprises, in order to provide some useful references and recommendations for the development, patent protection countermeasure and intellectual property strategy of coagulation factor Xa for domestic pharmaceutical enterprises.
